A cannabidiol (CBD) focused pharmaceutical technology company has demonstrated how long CBD can remain in the body, depending on the delivery system.
On Monday, October 19, Israel-based Innocan Pharma Corporation revealed the results of a study showing that CBD remained in mice brains 41 days after administration.
Rather than oral administration, the mice were injected subcutaneously with Innocan’s CBD Liposome Platform Technology (LPT).
Innocan reports that they detected no amounts of CBD in the mice’s brains 22 days after injecting them with free CBD without the LPT delivery system.
According to Innocan, the LPT’s delivery system’s prolonged and controlled release demonstrated continuous clinically relevant CBD concentrations in the blood for an extended period.
Innocan believes the study results are a good predictor of CBD exposure when administered in humans.
“Our nexus between deep scientific expertise and robust pharma commercialization know-how is, once again, showing its results,” says Innocan Pharma CEO Iris Bincovich. “We hope that such valuable breakthroughs will help in positioning Innocan as a substantial player in the CBD Pharma industry.”
According to Innocan, CBD’s continuous and long blood presence through local administration appears to be superior to oral administration in two ways.
The first is that it allows for a single administration of CBD instead of daily doses.
The second is that it helps overcome CBD’s low oral bioavailability, which is 10 to 20 percent.
Innocan says its delivery system’s superior pharmacokinetic (PK) profile may achieve controlled CBD concentration in the blood and result in better clinical outcomes.
“This is yet another major step-up in our research, showing measurable evidence to the relative and robust bioavailability when administered through our LPT,” says Hebrew University of Jerusalem Professor Chezy Barenholz. “Such results serve as a better predictor to human PK profile.”
Innocan Pharma Ltd. Has entered into a global, exclusive research and license agreement with the Hebrew University of Jerusalem’s commercial branch, the Yissum Research and Development Company.
Through the agreement, they will design, prepare, characterize, and evaluate hydrogels containing liposomes loaded with CBD or other cannabinoids.
